Trial Profile

An Open-Label, Pilot Study of Samarium - Sm 153 Lexidronam (Quadramet) in Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 22 Aug 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Samarium 153 lexidronam (Primary) ; Pamidronic acid; Zoledronic acid
Indications Bone metastases; Multiple myeloma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

13 Aug 2018 Status changed from active, no longer recruiting to completed.
28 Aug 2017 Planned End Date changed from 1 May 2016 to 1 May 2018.
28 Aug 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com